| SFDA Approved Use |
Indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult patients and paediatric patients aged 10 years and older:
-Patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4.4 and 5.1). or -Patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI |
|---|
An official government website affiliated with the Government of the Kingdom of Saudi Arabia.
Thu 25 Jun 2026
Beta version
Official Saudi government website domains end with gov.sa
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
Government websites use the protocol. HTTPS for encryption and security.
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.